Should We Still Have Bare-Metal Stents Available in Our Catheterization Laboratory?

Publication date: 1 August 2017
Source:Journal of the American College of Cardiology, Volume 70, Issue 5
Author(s): Antonio Colombo, Francesco Giannini, Carlo Briguori
The introduction of bare-metal stents (BMS) has represented a major advancement over plain old balloon angioplasty in the management of coronary artery disease. However, the high rates of target lesion revascularization associated with use of BMS have led to the development of drug-eluting stents, which require prolonged dual antiplatelet therapy due to the increased risk of late and very late stent thrombosis. The improvements in newer-generation drug-eluting stents have translated into better safety and efficacy compared with earlier generation and BMS, thus allowing shorter dual antiplatelet therapy duration. Here, we aim to provide reasons as to why we still need BMS in our cardiac catheterization laboratory.

Graphical abstract

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uus4k3
via IFTTT